Management of borderline ovarian tumors

Bois, Andreas du; Trillsch, Fabian; Mahner, Sven; Heitz, Florian; Harter, Philipp

doi:10.1093/annonc/mdw090

Cited by 74 publications

(79 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chemotherapy and radiotherapy may have a negative effect on BOT prognosis and patients' overall health due to toxicity and complications. In addition, there is no clear evidence that chemotherapy can reduce BOT recurrence . Given the unestablished efficacy of chemotherapy and a poor model fit when this variable was included, we excluded chemotherapy from the final model.…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have shown that supplemental chemotherapy or radiotherapy did not have benefit in BOT treatment, even in advanced-stage BOT or BOT with invasive peritoneal implants. 27,28 Chemotherapy and radiotherapy may have a negative effect on BOT prognosis and patients' overall health due to toxicity and complications. In addition, there is no clear evidence that chemotherapy can reduce BOT recurrence.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, there is no clear evidence that chemotherapy can reduce BOT recurrence. 28 Given the unestablished efficacy of chemotherapy and a poor model fit when this variable was included, we excluded chemotherapy from the final model.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Recurrence rate and associated factors of borderline ovarian tumors in the south of Vietnam

Duong

Tran

et al. 2019

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Aim This study aimed to determine the recurrence rate and related risk factors of borderline ovarian tumors (BOT). Methods We conducted a retrospective cohort study with 433 patients who were surgically treated for primary BOT at Tu Du Hospital from 11/2008 to 09/2015. We used the life table method to estimate the cumulative recurrence rate. We used the log–rank test and Cox proportional hazard model to determine recurrence‐associated factors. Results Median follow‐up time was 43 months (range: 3–105 months). Eighteen patients developed recurrence. The cumulative BOT recurrence rates at year 1, 2, 3 and 4 were 1.2% (95% confidence interval [CI] = 0.5–2.8), 3.0% (95% CI = 1.7–5.2), 4.6% (95% CI = 2.9–7.4), and 5.1% (95% CI = 3.2–8.0), respectively. In the final multivariate model, a higher recurrence rate was significantly associated with primary tumor stages (stage I vs stages II and III, hazards ratio [HR] = 4.44, 95% CI = 1.60–12.38), pre‐operative tumor's capsule rupture (HR = 4.14, 95% CI = 1.78–9.64), and cystectomy (HR = 5.33, 95% CI = 1.43–19.91). Conclusion The overall BOT recurrence rate in women in southern Vietnam was moderate. Primary tumor stage, capsule rupture, and cystectomy were main factors associated with BOT recurrence. Appropriate follow‐up strategies for patients with high‐risk factors are needed for early detection and management of recurrence.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Recurrence rate and associated factors of borderline ovarian tumors in the south of Vietnam

Duong

Tran

et al. 2019

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

“…BOTs comprise of 10-20% of all ovarian neoplasms 4. The incidence of BOTs is 1.8–4.8 cases per 100,000 females per year 5.…”

Section: Introductionmentioning

confidence: 99%

Borderline tumors of the ovary: A clinicopathological study

et al. 2017

View full text Add to dashboard Cite

Objective:To report experience with borderline ovarian tumors (BOTs) in a developing country like Pakistan with limited resources and weak database of health system.Methods:Patients with BOTs managed at Shaukat Khanum Cancer hospital, Lahore, Pakistan from 2004 to 2014 were included and reviewed retrospectively. Data was recorded on histopathological types, age, CA-125, stage of disease, treatment modalities and outcomes.Results:Eighty-six patients with BOT were included with a median age of 35 years. Forty-two (49%) patients had serous BOTs and 43 (50%) had mucinous BOTs, while one (1%) had mixed type. Using FIGO staging, 80 patients had stage I; two patients had IIA, IIB and stage III each. Median follow-up time was 31.5 months. All patients had primary surgery. Seventy (81%) patients underwent complete surgical resection of tumor. Forty-three (50%) patients had fertility preserving surgery. Seventy-three (85%) patients remained in remission. Recurrent disease was observed in 13 (15%) patients. Median time to recurrence was 22 months. On further analysis, age above forty years, late stage at diagnosis and incomplete surgery were significantly associated with invasive recurrence.Conclusion:Despite a low malignant potential, relapses may occur in patients above forty years of age, incomplete surgery and staging information and advanced stage at presentation. Fertility sparing surgery should be considered in young patients. Complete excision of tumor and prolonged follow-up are advised because recurrence and transformation to invasive carcinoma may occur.

show abstract

“…BOTs often occur in young women, however the absence of stromal invasion warrant a better prognosis compared to ovarian carcinoma [8,9]. Neverthless, since the standard treatment of BOTs is usually surgery, the fertility of these women may be affected [10]. Identifying the genetic background for diagnosis and prognosis should avoid a radical resection and help in developing new targeted therapies, especially in younger woman with desire of childbearing.…”

Section: Introductionmentioning

confidence: 99%

Role of Retinoblastoma Protein Family (Rb/P105 And Rb2/P130) Expression in the Hystopathological Classification of Borderline Ovarian Tumors

Masciullo

Valdivieso

Amadio

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Borderline ovarian tumors (BOT) are uncommon but not rare epithelial ovarian neoplasms, intermediate between benign and malignant categories. Emerging knowledge supports the notion that subtypes of borderline ovarian tumors comprise distinct biologic, pathogenetic, and molecular entities, precluding a single unifying concept for BOT. Therefore, the identification of valuable markers for the diagnosis and classification of these tumors is in need. Among the molecular candidates, the Retinoblastoma (Rb) family members Rb/p105 and Rb2/p130 seem to play a pivotal role in ovarian cancer. In particular, Rb/p105, when in the unphosphorylated form, acts as a growth suppressor and plays a pivotal role in the negative control of the cell cycle and in tumor progression; whereas, the phosphorylated form (p-pRB) activates genic transcription and cellular proliferation. While Rb/p105 is ubiquitously confined to the nuclei of cycling and quiescent cells, Rb2/p130 activity is also regulated by intracellular localization. According to this premise, Rb family members could represent a novel marker in diagnosis and classification risk for patients with borderline ovarian tumors (BOT). Aims In this study, we evaluated the immunohistochemical expression and subcellular localization of proteins of the retinoblastoma (Rb) gene family: Rb/p105 and Rb2/p130 in 65 ovarian borderline tumors (26 serous, 19 sero-mucinous and 20 mucinous subtypes). Results Statistically significant differences were found in nuclear and cytoplasmic expression of Rb/p105 and Rb2/p130 according to different examined histotypes. In detail, the nuclear expression of Rb/p105 and Rb2/p130 was more frequently detected in serous (84.6%) than sero-mucinous (42.1%) and mucinous (50%) types. Conversely, the cytoplasmic expression of Rb2/p130 was not detected in serous tumors and frequently observed in mucinous subtypes (80%). Conclusions Our findings suggest that Rb proteins do not play a key role in the tumor progression of serous borderline tumors since they are always located in the nucleus and no cases showed a cytoplasmic localization. By contrast, the observed higher cytoplasmic expression of Rb2/p130 in mucinous BOTs (intestinal) types, is suggestive of Rb proteins involvement in the cancerogenesis pathway of mucinous ovarian tumors. Our results also suggest that mucinous BOTs of intestinal type, exhibiting low nuclear and high cytoplasmic levels of Rb2/p130 might potentially be considered a high risk category of malignant evolution. Further studies on larger series are needed in order to clarify how BOTs could be stratified in different prognostic groups according to their Rb proteins immunohistochemical profile.

show abstract

Management of borderline ovarian tumors

Abstract: More studies on BOT are needed and longer follow-up and better characterization of high-risk subtypes are crucial to better understand long-term risk of BOT and avoid the rare but the fatal outcome in those few patients being undertreated by the current management strategies.

Cited by 74 publications

References 40 publications

Recurrence rate and associated factors of borderline ovarian tumors in the south of Vietnam

Recurrence rate and associated factors of borderline ovarian tumors in the south of Vietnam

Borderline tumors of the ovary: A clinicopathological study

Role of Retinoblastoma Protein Family (Rb/P105 And Rb2/P130) Expression in the Hystopathological Classification of Borderline Ovarian Tumors

Contact Info

Product

Resources

About